Cargando…
Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection
Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy...
Autores principales: | Karlafti, Eleni F., Hatzitolios, Apostolos I., Karlaftis, Anastasios F., Baltatzi, Maria S., Koliakos, Georgios G., Savopoulos, Christos G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831737/ https://www.ncbi.nlm.nih.gov/pubmed/24302832 http://dx.doi.org/10.4103/0975-7406.120067 |
Ejemplares similares
-
Effect of Central Sympathoinhibition With Moxonidine on Sympathetic Nervous Activity in Polycystic Ovary Syndrome—A Randomized Controlled Trial
por: Shorakae, Soulmaz, et al.
Publicado: (2018) -
Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study
por: Karagiannis, Asterios, et al.
Publicado: (2009) -
Effects of Lifestyle Measures, Antiobesity Agents, and Bariatric Surgery on Serological Markers of Inflammation in Obese Patients
por: Tziomalos, Konstantinos, et al.
Publicado: (2010) -
Neuronal Activation in the Central Nervous System of Rats in the Initial Stage of Chronic Kidney Disease-Modulatory Effects of Losartan and Moxonidine
por: Palkovits, Miklós, et al.
Publicado: (2013) -
Acute hepatitis associated with Q fever in a man in Greece: a case report
por: Pape, Magdalini, et al.
Publicado: (2007)